Clinical Trial Update: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating CAR-T cells targeting CD19 and BCMA in relapsed or refractory multiple myeloma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Shanxi Province Cancer Hospital | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN